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Background: Metabolites of eicosapentaenoic acid exert various
physiologic actions. 17,18-Epoxyeicosatetraenoic acid (17,18-
EpETE) is a recently identified new class of antiallergic and
anti-inflammatory lipid metabolite of eicosapentaenoic acid, but
its effects on skin inflammation and the underlying mechanisms
remain to be investigated.
Objective: We evaluated the effectiveness of 17,18-EpETE for
control of contact hypersensitivity in mice and cynomolgus
macaques. We further sought to reveal underlying mechanisms
by identifying the responsible receptor and cellular target of
17,18-EpETE.
Methods: Contact hypersensitivity was induced by topical
application of 2,4-dinitrofluorobenzene. Skin inflammation and
immune cell populations were analyzed by using flow
cytometric, immunohistologic, and quantitative RT-PCR
analyses. Neutrophil mobility was examined by means of
imaging analysis in vivo and neutrophil culture in vitro. The
receptor for 17,18-EpETE was identified by using the TGF-a
shedding assay, and the receptor’s involvement in the anti-
inflammatory effects of 17,18-EpETE was examined by using
KO mice and specific inhibitor treatment.
Results: We found that preventive or therapeutic treatment with
17,18-EpETE ameliorated contact hypersensitivity by inhibiting
neutrophil mobility in mice and cynomolgus macaques.
17,18-EpETE was recognized by G protein–coupled receptor
(GPR) 40 (also known as free fatty acid receptor 1) and inhibited
chemoattractant-inducedRacactivationandpseudopod formation
in neutrophils. Indeed, the antiallergic inflammatory effect of
17,18-EpETEwas abolished in the absence or inhibition ofGPR40.
Conclusion: 17,18-EpETE inhibits neutrophil mobility through
GPR40 activation, which is a potential therapeutic target to
control allergic inflammatory diseases. (J Allergy Clin Immunol
2018;142:470-84.)
Key words: 17,18-Epoxyeicosatetraenoic acid, G protein–coupled
receptor 40, v3 fatty acid, contact hypersensitivity, dermatitis,
neutrophil
Omega-3 (v3) and v6 polyunsaturated fatty acids are essential
fatty acids because they cannot be produced within the mamma-
lian body and therefore must be ingested from the diet. The major
v3 fatty acid in dietary oils is a-linolenic acid (ALA), which is
particularly abundant in linseed and perilla oils.1,2 Fatty acid de-
saturase and elongase metabolize ALA into eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), which are predom-
inant in fish oils.1,2 Several lines of evidence have revealed that
dietary intake of these oils shows antiallergic and/or anti-
inflammatory properties.1-5
Recent advances in lipidomics using liquid chromatography–
tandem mass spectrometry have led to identification of a new
class of lipid metabolites that play a pivotal role in the control of
allergy and inflammation.6-8 These metabolites are derived from
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EPA (eg, E-series resolvins) and DHA (D-series resolvins,
maresins, and protectins) and are generated through the combined
activity of COX-2, lipoxygenase, and cytochrome P450 (CYP),
which are central to various diseases, including intestinal
inflammation, rheumatoid arthritis, asthma, diabetes, and
atherosclerosis.6-8
Recently, we showed that feeding mice a diet containing
linseed oil (also known as flaxseed oil), a dietary oil enriched in
ALA, ameliorated ovalbumin-induced allergic diarrhea.9 Lipido-
mics analysis revealed that concentrations of 17,18-
epoxyeicosatetraenoic acid (17,18-EpETE) were increased
significantly in the intestines of mice maintained on the linseed
oil diet. Furthermore, intraperitoneal administration of synthetic
17,18-EpETE inhibited the development of food allergy in
mice.9 Separate studies demonstrated that 17,18-EpETE and its
hydroxyl derivative, 12-OH-17,18-EpETE, were also effective
for the control of other allergic and inflammatory diseases, such
as asthma,10 choroidal neovascularization,11 and peritonitis.12
These findings suggest collectively that 17,18-EpETE is a new
EPA metabolite that can be used to control allergic and inflam-
matory diseases; however, its effects on skin inflammation and the
molecular and cellular mechanisms underlying the antiallergic
and anti-inflammatory properties of 17,18-EpETE remain to be
investigated. The anti-inflammatory effects of 17,18-EpETE are
mediated by nuclear receptor of peroxisome proliferator-
activated receptor (PPAR) g.10 In addition to nuclear receptors,
G protein–coupled receptors (GPRs) act as cell-surface receptors
for several types of free fatty acids. For example, GPR41 and
GPR43 are activated by short-chain fatty acids, such as acetate,
propionate, and butyrate.13 GPR84 acts as a receptor for
medium-chain fatty acids, such as capric acid and lauric acid.14
GPR40 and GPR120 respond to long-chain fatty acids, including
palmitic acid, EPA, and DHA.15,16 However, it remains unclear
which receptors are activated by 17,18-EpETE.
The incidence of allergic and inflammatory skin diseases is
increasing worldwide.17,18 Contact dermatitis is a major allergic
skin disease that affects 15% to 20% of the world’s population.18
Murinemodels of contact dermatitis arewell established as contact
hypersensitivity and have revealed the molecular and cellular
immunopathologic pathways in the sensitization and elicitation
phases of the disease.19 In the sensitization phase of contact hyper-
sensitivity, keratinocytes are activated in response to exposure to an
allergen or hapten and consequently produce inflammatory media-
tors, such as prostaglandin E2, TNF-a, and IL-1b. These mediators
induce thematuration of skin dendritic cells (DCs) and their migra-
tion to draining lymph nodes, where DCs activate naive T cells for
the generation of allergen-specific effector or pathologic T cells.19
In the elicitation phase of contact hypersensitivity, neutrophils and
memory T cells expressing CXCR2 and CXCR3, respectively,
infiltrate into the skin in response to chemokines and adhesion
molecules, including the neutrophil attractants CXCL1 and
CXCL2 and the T-cell attractants CXCL9, CXCL10, and intercel-
lular adhesion molecule (ICAM) 1 in the context of increased
vascular permeability.19 Granulocyte colony-stimulating factor
(G-CSF) contributes to neutrophil infiltration also.20 In addition,
B cells play a role in the recruitment of T cells by producing
IgM antibody, which induces complement activation and mast
cell degranulation.21 On infiltration into the skin, T cells are further
activated by cutaneous antigen-presenting cells and produce in-
flammatory cytokines (eg, IFN-g and IL-17A). Indeed, the deple-
tion of neutrophils by using cell-specific antibody20,22,23 or,
alternatively, gene deletion of IFN-g24 or IL-17A25 impairs the
development of contact hypersensitivity. A recent study has shown
that formation of clusters of DCs in the skin, known as inducible
skin-associated lymphoid tissue (iSALT), is induced by macro-
phages and plays an important role in the activation and prolifera-
tion of memory T cells during the elicitation phase.26
Despite the numerous detailed studies on allergic skin inflam-
mation, currently approved medicines against skin inflammation
include only steroids and immunosuppressants (eg, calcineurin
inhibitors).17 Because side effects of these drugs include skin thin-
ning and infectious diseases, new types of immunotherapy and
medicines with high safety and efficacy are needed. In this context
several recent studies have indicated the possible application of
lipid mediators for the control of skin inflammation. For example,
treatment of mice with resolvin E1, an EPA-derived metabolite,
attenuated skin inflammation.27,28 Therefore lipid mediators
appear to be promising targets for the treatment of allergic skin
inflammation, including contact dermatitis. In the current study
we evaluated the effects of 17,18-EpETE on the treatment of con-
tact hypersensitivity in mice and cynomolgus macaques and inves-
tigated the molecular and cellular mechanisms underlying its
antiallergic and anti-inflammatory properties.
METHODS
Animals
Female wild-type C57BL/6 mice (age 6-8 weeks) were purchased from
Japan SLC (Hamamatsu, Japan) or CLEA Japan (Tokyo, Japan) and kept for at
least 1 week before experiments in the specific pathogen-free animal facility at
the National Institutes of Biomedical Innovation, Health and Nutrition
(NIBIOHN; Osaka, Japan). Ffar12/2 mice were generated previously16 and
bred and maintained in the animal facility at NIBIOHN. Mice were killed by
means of cervical dislocation after achievement of anesthesia with isoflurane
(Foranel AbbVie, North Chicago, Ill). For the pharmacokinetic analysis,
6-week-old male Crl:CD (SD) rats received 17,18-EpETE (2 mg/kg adminis-
tered orally). Plasma samples were collected at 0.25, 0.5, 1, 2, 4, 8, and 24 hours
after administration, and the amount of 17,18-EpETE was measured by using
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liquid chromatography–tandem mass spectrometry.9 Female cynomolgus ma-
caques (Macaca fascicularis; age, 14-22 years; weight, 2-3 kg) weremaintained
at the Tsukuba Primate ResearchCenter, NIBIOHN, according to the ‘‘Rules for
animal care and management of Tsukuba Primate Center’’29 and the ‘‘Guiding
principles for animal experiments using nonhuman primates’’ formulated by the
Primate Society of Japan. All experiments were conducted in accordance with
the guidelines of the Animal Care and Use Committee of NIBIOHN and Osaka
University and the Committee on the Ethics of Animal Experiments of NI-
BIOHN and Osaka University (DS25-2, DS25-3, and DS26-41).
Bone marrow transplantation
Bonemarrow cells were prepared from the femurs and tibiae of 8-week-old
donor mice. Recipient mice (age, 6 weeks) were X-irradiated (dose, 8 Gy;
MBR-1520R-3; Hitachi, Tokyo, Japan) 6 hours before injection of bone
marrow cells (13 107 cells per recipient) into the tail vein. Transplanted recip-
ient mice were allowed to recover for at least 8 weeks before their use in
experiments.
Induction of contact hypersensitivity in mice
Contact hypersensitivity was induced, as described previously with
modifications.26 Briefly, the abdominal skin of each mouse was shaved and
then treated with 25 mL of 0.5% (vol/vol) 2,4-dinitrofluorobenzene (DNFB;
Nacalai Tesque [Kyoto, Japan] or Sigma [St Louis, Mo]) dissolved in a
mixture of acetone (Nacalai Tesque or Wako [Tokyo, Japan]) and olive oil
(Nacalai Tesque or Wako; acetone/olive oil, 4:1). After 5 days, the fronts
and backs of both ears were challenged with 0.2% (vol/vol) DNFB (10 mL
per site). At 48 hours after DNFB treatment, ear thickness was measured
with a micrometer (model MDC-25MJ 293-230; Mitsutoyo, Kawasaki,
Japan).Mice received 17,18-EpETE (dose: 100 ng administered intraperitone-
ally or 1 mg administered orally or topically; Cayman Chemical, Ann Arbor,
Mich), 17,18-dihydroxy-eicosa-5,8,11,14-tetraenoic acid (17,18-diHETE;
dose: 100 ng administered intraperitoneally; Cayman Chemical), TAK-875
(dose: 60 mg administered intraperitoneally; ChemScene, Monmouth Junc-
tion, NJ), resolvin E1 (dose: 200 ng administered intraperitoneally; Cayman
Chemical), or 0.5% (vol/vol) ethanol dissolved in PBS as a vehicle control
30 minutes before DNFB stimulation. In some experiments mice received
GW1100 (1 mg/kg administered intraperitoneally; Focus Biomolecules, Ply-
mouth Meeting, Pa) 30 minutes before 17,18-EpETE treatment. In some ex-
periments mice were topically treated with dexamethasone (Tokyo
Chemical Industry, Tokyo, Japan), as described previously with modifica-
tions.30 In brief, abdominal skin (25 mL) and ears (10 mL per site) were topi-
cally treated with 0.12% (vol/vol) dexamethasone at days 0 and 5,
respectively, 30 minutes before stimulation with DNFB.
Induction of contact hypersensitivity in cynomolgus
macaques
The abdominal skin of cynomolgus macaques was clipped free of hair and
then sensitized with 2.5 mL of 0.5% (vol/vol) DNFB dissolved in a mixture of
acetone and olive oil (ratio, 4:1). After 5 days, the dorsal skin was shaved and
challenged with 700 mL of 0.2% (vol/vol) DNFB; 48 hours later, each animal
was treated with 17,18-EpETE (150 mg administered topically) or vehicle.
Skin samples were obtained by means of biopsy 72 hours after 17,18-EpETE
application.
Cell isolation and flow cytometric analysis
Cell isolation and flow cytometry were performed, as described previously
with modification.28 The ears were split into dorsal and ventral skin, and the
cartilage was removed by scratching with tweezers. Skin was cut into small
pieces by using scissors and incubated in 2 mg/mL collagenase (Wako) in
RPMI 1640 medium (Sigma-Aldrich) containing 2% (vol/vol) newborn calf
serum (Equitech-Bio, Kerrville, Tex) for 60 to 90 minutes at 378C with stir-
ring. Cell suspensions were filtered through cell strainers (pore size, 70 mm;
BD Biosciences, Franklin Lakes, NJ) and stained with an anti-CD16/32
mAb (TruStain fcX; BioLegend, San Diego, Calif; 101320; 1:100) to avoid
nonspecific staining. Cells were further stained with the following fluores-
cently labeled mAbs: fluorescein isothiocyanate (FITC)–anti-Ly6G (Bio-
Legend; 127606; 1:100), FITC–anti-Gr1 (BioLegend; 108406, 1:100),
allophycocyanin (APC)-Cy7–anti-CD11b (BioLegend; 101226; 1:100),
phycoerythrin (PE)-Cy7–anti-CD11c (BioLegend; 117318; 1:100), PE-
Cy7–anti-F4/80 (BioLegend; 123114; 1:100), PE–anti-F4/80 (BioLegend;
123110; 1:100), PE–anti-Langerin (Thermo Fisher Scientific, Waltham,
Mass; 12-2075-82, 1:100), Alexa Fluor 647–anti–I-Ab (BioLegend; 116412;
1:100), Alexa Fluor 647–anti–Siglec-F (BD Biosciences; 562680, 1:100),
PE–anti–c-Kit (BD Biosciences; 553355, 1:100), APC–anti-FcεRI (Thermo
Fisher Scientific; 17-5898-82, 1:100), PE–anti-CD19 (BD Biosciences;
557399, 1:100), PE-Cy7–anti-B220 (BD Biosciences; 552772, 1:100), PE–
anti-CD18 (BD Biosciences; 553293; 1:100), PE–rat IgG2a isotype control
(BDBiosciences; 553930, 1:100), PE–anti-CXCR2 (R&DSystems,Minneap-
olis, Minn; FAB2164P; 1:10), BV421–anti-CD3ε (BioLegend; 100336,
1:100), BV421–anti-CD45 (BioLegend; 103133, 1:100), BV421–anti-
CD11c (BioLegend; 117330, 1:25), BV421–anti-F4/80 (BioLegend;
123124, 1:100), APC–Annexin V (BioLegend; 640919; 1:20), PE–anti-Ki67
(BioLegend; 652404; 1:100), PE–anti–Fas ligand (FasL; BD Biosciences;
555293, 1:100), PE–hamster IgG1 isotype control (BD Biosciences; 553972,
1:100), APC–anti-perforin (Thermo Fisher Scientific; 17-9392, 1:40), APC–
rat IgG2a isotype control (BioLegend; 400512, 1:40), FITC–anti-CD45 (BD
Biosciences; 553079; 1:100), peridinin-chlorophyll-protein complex–anti-
CD4 (BioLegend; 100432; 1:100), PE–anti–IFN-g (BioLegend; 505808;
1:100), PE–rat IgG1 isotype control (BioLegend; 401906, 1:100), BV421–
anti–T-cell receptor b (BioLegend; 109230; 1:100), and Alexa Fluor 647–
anti–IL-17A (BD Biosciences; 560184; 1:100).
Cells were treated for 60 minutes with brefeldin A (BioLegend) during
collagenase treatment to stain intracellular cytokines. After viability and cell-
surface markers were stained, cells were fixed and permeabilized (Cytofix/
Cytoperm Fixation/Permeabilization Kit; BD Biosciences), according to the
manufacturer’s protocol. Dead cells were detected by using Via-Probe (BD
Biosciences; 555816), 7-aminoactinomycin D (BioLegend; 420404; 1:100),
or Zombie-NIR Fixable Viability Kit; 423106; 1:100) and excluded from
analysis. Samples were analyzed (MACSQuant [Miltenyi Biotec, Bergish
Gladbach, Germany] or FACSAria [BD Biosciences]), and cells were isolated
(FACSAria) by using flow cytometry. Data were analyzed with FlowJo 9.9
software (TreeStar, Ashland, Ore).
Reverse transcription and quantitative PCR analysis
Total RNA was isolated from purified cells by using Sepazol (Nacalai
Tesque) and chloroform (Nacalai Tesque), precipitated with 2-propanol
(Nacalai Tesque), and washed with 75% (vol/vol) ethanol (Nacalai Tesque).
RNA samples were incubated with DNase I (Invitrogen, Carlsbad, Calif) to
remove contaminating genomic DNA and then reverse transcribed into cDNA
(Superscript III reverse transcriptase, VIRO cDNA Synthesis Kit; Invitrogen).
Ears were placed in XXTuff microvials (BioSpec Products, Bartlesville,
Okla) containing 800 mL of PBS and crushed by using stainless-steel beads
(4.84 and 3.24, TOMY) for 5 pulses (4800 rpm, 10 seconds each; Minibead-
beater, BioSpec Products) to isolate RNA from ear tissues; samples were put
on ice for 10 seconds between pulses. Samples were centrifuged (9100g for
20 minutes at 48C), and the supernatant was processed to obtain total RNA
(Relia Prep RNA Tissue Miniprep System; Promega, Tokyo, Japan), which
was reverse transcribed, as described for purified cells.
Quantitative PCR analysis was performed with LightCycler 480 II (Roche,
Basel, Switzerland) with FastStart Essential DNA Probes Master (Roche) or
SYBR Green I Master reagents (Roche). Primer sequences were
as follows: cathelicidin sense, 59-gacaccaatctctaccgtctcc-39; cathelicidin
antisense, 59-cacagacttgggagtatctgga-39; b-defensin 1 sense, 59-ggctgccac-
cactatgaaa-39;b-defensin 1 antisense, 59-tgtgagaatgccaacacctg-39;b-defensin
2 sense, 59-tgctgcctccttttctcatatac-39; b-defensin 2 antisense, 59-tcaag
ttctgcttcgtatccaa-39; Tnfa sense, 59-ctgtagcccacgtcgtagc-39; Tnfa antisense,
59-ttgagatccatgccgttg-39; chitinase 3–like 3 (Chi3l3) sense, 59-aagaacactgagct
aaaaactctcct-39; Chi3l3 antisense, 59-gagaccatggcactgaacg-39; Cxcl1 sense,
59-gactccagccacactccaac-39; Cxcl1 antisense, 59-tgacagcgcagctcattg-39;
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Cxcl2 sense, 59-aaaatcatccaaaagatactgaacaa-39; Cxcl2 antisense, 59-ctttg
gttcttccgttgagg-39; G-CSF sense, 59-cctggagcaagtgaggaaga-39; G-CSF anti-
sense, 59-ggggtgacacagcttgtagg-39; Ffar1 sense, 59-taggactggcttctggtgct-39;
Ffar1 antisense, 59-ctgcagagaaaagaatgtcacaa-39; Il10 sense, 59-cagagccaca
tgctcctaga-39; Il10 antisense, 59-tgtccagctggtcctttgtt-39; Actb sense, 59-aaggcc
aaccgtgaaaagat-39; and Actb antisense, 59-gtggtacgaccagaggcatac-39.
Histologic analysis
Frozen tissue was analyzed histologically, as described previously with
some modification.31 Ear samples were washed with PBS (Nacalai Tesque) on
ice and frozen in Tissue-Tek OCT compound (Sakura Finetek, Tokyo, Japan)
in liquid nitrogen. Frozen tissue sections (6 mm) were prepared by using a
cryostat (model CM3050 S) and fixed for 30 minutes at 48C in prechilled
95% ethanol (Nacalai Tesque), followed by 1 minute at room temperature
in prechilled 100% acetone (Nacalai Tesque).
For staining with hematoxylin and eosin, tissue sections were washed with
running water for 10 minutes, stained with Mayer hematoxylin solution (Wako)
for 10 minutes, and washed with running water for 30 minutes. Tissue sections
were then stained with 1% eosin Y solution (Wako) for 1 minute, washed with
runningwater for 10 seconds, and dehydrated through increasing concentrations
of ethanol (1 minute at each concentration, 70% to 100%; Nacalai Tesque).
Tissue sections underwent final dehydration in xylene (Nacalai Tesque) for
3 minutes and were mounted in Permount (Falma, Tokyo, Japan).
For immunohistologic analysis, tissue sections were washed with PBS for
10 minutes and then blocked in 2% (vol/vol) newborn calf serum in PBS for
30minutes at room temperature in an incubation chamber (CosmoBio, Tokyo,
Japan). Tissue sections were incubated with primary antibodies in 2% (vol/
vol) newborn calf serum in PBS for 16 hours at 48C in the incubation chamber,
washed once for 5 minutes each in 0.1% (vol/vol) Tween-20 (Nacalai Tesque)
in PBS and PBS only, and then stained with secondary antibodies in 2% (vol/
vol) newborn calf serum in PBS for 30 minutes at room temperature in the
incubation chamber. To visualize nuclei, tissue sections then were washed
twice (5 minutes each) with PBS and stained with 49-6-diamidino-2-
phenylindole dihydrochloride (DAPI; 1 mmol/L; AAT Bioquest, Sunnyvale,
Calif) for 10 minutes at room temperature in the incubation chamber. Finally,
tissue sections were washed twice with PBS, mounted in Fluoromount
(Diagnostic BioSystems, Pleasanton, Calif), and examined under a fluores-
cence microscope (model BZ-9000; Keyence, Osaka, Japan).
Paraffinated sections were trimmed to a thickness of 5 mm by using a
sliding microtome (model SM2010R; Leica Biosystems, Wetzlar, Germany)
and subsequently deparaffinized by incubating in xylene (Nacalai Tesque) for
5 minutes, followed by rehydration through decreasing concentrations of
ethanol (Nacalai Tesque) from 100% to 70% (1 minute at each concentration)
at room temperature. Deparaffinized sections were stained with hematoxylin
and eosin, as described above. For staining with an anti-CD66abce antibody,
antigen retrieval was conducted by heating sections in 10 mmol/L sodium
citrate (pH 6.0) for 10 minutes in a microwave oven before deparaffinization.
For histologic analysis, the following antibodies and reagents were used:
purified anti-CD11c mAb (BioLegend; 117302; 1:50); purified anti-CD45
mAb (BioLegend; 103102; 1:100); purified anti-CD3ε mAb (BioLegend;
100302; 1:100); Cy3–anti–Armenian hamster IgG (Jackson ImmunoResearch
Laboratories, West Grove, Pa; 127-165-160; 1:200), Alexa Fluor 488–anti-rat
IgG (Thermo Fisher Scientific; A-11006; 1:200), FITC–anti-Ly6G mAb
(BioLegend; 127606; 1:100), biotin–anti-human CD66abce (Miltenyi Biotec;
130093156; 1:10), and FITC–streptavidin (BD Biosciences; 554060; 1:100).
Cell nuclei were visualized by staining with DAPI (1mmol/L; AATBioquest),
as described above.
In vivo labeling of neutrophils
Intravascular labeling of neutrophils was performed, as described previ-
ously with modification.32,33 In the DNFB-induced contact hypersensitivity
model on day 7, mice were injected intravenously with 1 mg of FITC–anti-
Ly6G mAb in PBS containing 1 mmol/L CaCl2 (Nacalai Tesque); 30 minutes
after injection, cells were isolated from ears and examined by using flow
cytometry.
In vitro neutrophil assay
The Rac activation assay was performed as previously described with
modification.34 Briefly, bone marrow–derived neutrophils were harvested by
using 70% Percoll and cultured in RPMI1640 medium containing 50 mmol/
L 2-mercaptoethanol (Life Technologies, Carlsbad, Calif), 10mmol/LHEPES
(Nacalai Tesque), 0.5% BSA (Nacalai Tesque), and 100 mg/mL penicillin-
streptomycin (Nacalai Tesque). Cultured neutrophils were treated with either
17,18-EpETE (100 nmol/L) or ethanol (vehicle) for 15 minutes, followed by
stimulation with 1 mmol/L N-formyl-methionyl-phenylalanine (fMLP;
Sigma-Aldrich) for 1 minute at 378C. After stimulation, neutrophils were
collected and lysed in 500 mL of lysis buffer (20 mmol/L HEPES [pH 7.4],
150 mmol/L NaCl, 1% Triton X-100, 4 mmol/L EDTA, and 4 mmol/L
EGTA) containing a protease-inhibitor cocktail (Sigma-Aldrich). The amount
of protein in each sample was quantified by using the BCA Protein Assay Kit
(Thermo Fisher Scientific). The volume of lysate containing 40 mg of protein
was incubated with 5mg of PAK1 PBD beads (Cell Biolabs, San Diego, Calif)
for 30 minutes at 48C with rotation. The beads were then washed 3 times with
lysis buffer and resuspended in Nu-PAGE sample buffer (Invitrogen) contain-
ing a reducing agent (Invitrogen). The resulting bead-purified samples and
whole-cell lysates were analyzed by means of Western blotting with Nu-
PAGE 4%-12% gels (Invitrogen), anti-Rac 1/2/3 polyclonal antibody (Cell
Signaling, Tokyo, Japan; 2465; 1:2500), anti-mouse b-actin (BioLegend;
643802; 1:1000), horseradish peroxidase–conjugated donkey anti-rabbit IgG
(BioLegend; 406401; 1:2500), and goat anti-mouse IgG (SouthernBiotech,
Birmingham, Ala; 1030-05; 1:8000). Western blot signals were detected by
using an image analyzer (model LAS-4000, ImageQuant; GE Healthcare, Lit-
tle Chalfont, United Kingdom).
For the F-actin polymerization assay, purified neutrophils (4 3 105 cells)
were suspended in HBSS containing 0.2% BSA and allowed to adhere to
fibronectin-coated coverslips (neuVitro, Vancouver, Wash) for 15 minutes in
5% CO2 incubation. Neutrophils were treated with either 17,18-EpETE
(20 nmol/L) or ethanol (vehicle) for 15 minutes and then stimulated with
1 mmol/L fMLP for 2 minutes in 5% CO2 incubation. Neutrophils were fixed
with 4% paraformaldehyde (Nacalai Tesque), permeabilized with 0.5%Triton
X-100 (Nacalai Tesque) in PBS, and stained in 100 nmol/L Acti-stain 488
phalloidin (Cytoskeleton, Denver, Colo) for 30 minutes at room temperature.
Finally, cell nuclei were stained by incubating neutrophils in DAPI for 30 sec-
onds at room temperature, and images were recorded (model TCS SP8; Leica
Microsystems, Wetzlar, Germany).
ELISA for G-CSF
The amount of G-CSF protein in the serumwas analyzed by using a Mouse
G-CSF ELISA Kit (R&D Systems). Absorbance at OD450 and OD570 was
measured by with the iMark microplate reader (Bio-Rad Laboratories, Hercu-
les, Calif).
ELISA for IgM antibody
The amount of serum IgM antibody was analyzed by using ELISA, as
described previously with modification.35 In brief, serum was prepared from
blood by means of centrifugation (5800g for 10 minutes). Supernatant was
used for ELISA as a serum sample. Nunc MaxiSorp flat-bottom 96-well plates
(Thermo Fisher Scientific) were coated with goat anti-mouse immunoglobulin
(H1L; Southern Biotech; 1010-01, 1:1000). Serum samples diluted serially
with PBS containing 1% (wt/vol) BSAwere applied to the plates. IgM antibody
was detected by using anti-mouse IgM–horseradish peroxidase (Southern
Biotech; 1020-05, 1:4000) and visualized by adding TMBmicrowell peroxidase
substrate (SeraCare Life Sciences, Milford, Mass). Thirty minutes after incuba-
tion, 0.5 mol/L HCl (Nacalai Tesque) was added, and absorbance at OD450 was
measured with the iMark microplate reader (Bio-Rad Laboratories).
TGF-a shedding assay
The TGF-a shedding assay was performed, as described previously.36 In
principle, activation of GPR was measured as ectodomain shedding of a
membrane-bound proform of alkaline-phosphatase–tagged TGF-a and its
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release into conditioned medium. Human embryonic kidney 293 (HEK293)
cells were transfected with a plasmid encoding alkaline phosphatase–tagged
TGF-a with or without a GPR-encoding plasmid.36 Because the TGF-a
shedding assay depends on a Gaq- or Ga12/13-mediated signaling pathway,
some GPRs required coexpression with a Ga chimeric protein. Specifically,
Gaq/i3 (consisting of the Gaq backbone with C-terminal sequences derived
from Gai3) was coexpressed in HEK293 cells in the assay for GPR84, and
Gaq/i1, Gaq/13, and Gaq/o were coexpressed in the assays for GPR41,
GPR43, and GPR120, respectively. Transfected HEK293 cells were seeded
in serum-free medium in a 96-well plate and stimulated with 17,18-EpETE,
17,18-diHETE, or EPA for 1 hour, followed by addition of para-
nitrophenylphosphate (a substrate for alkaline phosphatase) and measurement
of para-nitrophenol production at a wavelength of 405 nm.
In vivo imaging
Contact hypersensitivity in micewas induced by using DNFB treatment, as
described above; at 12 hours after elicitation, ear skin was observed by using
2-photon excitation microscopy. Neutrophils were visualized by means of
intravenous injection of 15 mg of FITC–anti-Ly6G mAb (BioLegend) 2 to
4 hours before imaging. Vessels were visualized by means of intravenous
injection of Qtracker 655 (Life Technologies) just before imaging. Neutrophil
mobility was monitored for 25 minutes before and after intravenous injection
of 25 mg of 17,18-EpETE at the same skin site. The imaging system was
composed of a 2-photon microscope (A1-MP; Nikon, Tokyo, Japan) driven by
a laser (Chameleon Vision II Ti Sapphire; Coherent, Santa Clara, Calif) tuned
to 900 nm and an inverted microscope equipped with a 203 objective lens
(NA, 0.75; Plan Fluor; Nikon). Fluorescent signals were detected through
band-pass emission filters at 525/50 nm (for FITC) and 660/52 nm (for
Qtracker 655). Tracking analysis was performed by using Imaris software
(Bitplane, Zurich, Switzerland).
Vascular permeability test
The vascular permeability assay was conducted, as reported previously
with modification.37 Evans blue dye (1% [wt/vol] solution; Nacalai Tesque)
was injected intravenously on day 7, 1 hour before mice were killed. Ears
were incubated in 1 mL of 3N KOH (Nacalai Tesque) at 378C overnight to
extract the Evans blue dye. Afterward, the supernatant was added to a tube
containing 1 mL of 1.24 mol/L H3PO4 and 3 mL of acetone; the contents
were mixed by means of vortexing, centrifuged (1280g for 15 minutes at
208C), and left to phase separate at room temperature for 10 minutes.
Absorbance of the aqueous phase (OD620) was measured with the SmartSpec
Plus (Bio-Rad Laboratories). The concentration of Evans blue dye was
calculated based on a standard curve of known amounts of the dye.
Statistics
Statistical significance was evaluated by using 1-way ANOVA for
comparison of multiple groups and the Mann-Whitney test for 2 groups by
using Prism 6 software (GraphPad Software, La Jolla, Calif). A P value of less
than .05 was considered significant.
RESULTS
17,18-EpETE ameliorates DNFB-induced contact
hypersensitivity
To examine the effects of 17,18-EpETE on skin inflammation,
we used a murine hapten-induced contact hypersensitivity model.
Mice were injected intraperitoneally with 17,18-EpETE or
vehicle 30 minutes before stimulation with DNFB as a
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FIG 1. Contact hypersensitivity is ameliorated by 17,18-EpETE but not its metabolite, 17,18-diHETE. A,Mice
were injected intraperitoneally with either 17,18-EpETE, 17,18-diHETE, or vehicle on days 0 and 5 at 30 mi-
nutes before DNFB application. Ear swelling was evaluated on day 7. Data are combined from 3 independent
experiments, and each point represents data from individual mice. Center values indicate medians. Statis-
tical significance of differences was evaluated by using 1-way ANOVA. B, Frozen ear sections were stained
with hematoxylin and eosin and analyzed by means of microscopy. Data are representative of 5 indepen-
dent experiments. Dexamethasone was applied as a positive control for inhibition of inflammation. Scale
bars 5 100 mm. C,Mice were injected intraperitoneally with either 17,18-EpETE or vehicle on the indicated
days at 30minutes before DNFB application. Ear swelling was evaluated on day 7. Data are combined from 3
independent experiments, and each point represents data from individual mice. Center values indicate me-
dians. Statistical significance of differences was evaluated by means of 1-way ANOVA: ***P < .001 and
****P < .0001.
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hypersensitivity, which was evaluated by measuring ear thickness
(see Fig E1, A, in this article’s Online Repository at
www.jacionline.org). We first examined ear swelling over time
and found that DNFB-induced ear swelling was maximal on
day 7 (see Fig E1, B) and that intraperitoneal injection with
17,18-EpETE ameliorated this inflammation (Fig 1, A, and see
Fig E1, B). 17,18-EpETE is known to be hydrolyzed by epoxide
hydrolase to form 17,18-diHETE.38 Consistent with our previous
findings regarding its lack of effect in intestinal allergy,9
17,18-diHETE had little effect on contact hypersensitivity
(Fig 1, A). Histologic analysis of ear sections supported
the finding that skin inflammation was ameliorated by
17,18-EpETE but not 17,18-diHETE (Fig 1, B). Human patients
with eczema have decreased levels of antimicrobial peptides in
the skin.39 Consistent with this evidence, various antimicrobial
peptides, including cathelicidin, b-defensin 1, and b-defensin 2,
showed decreased expression in our DNFB-induced contact
hypersensitivity mouse model, and 17,18-EpETE did not
influence the expression of these antimicrobial peptides (see Fig
E2 in this article’s Online Repository at www.jacionline.org).
We next treated mice intraperitoneally with 17,18-EpETE at
various time points at both the sensitization and elicitation
phases of contact hypersensitivity (days 0 and 5), at the elicitation
phase only (day 5), or after elicitation only (day 6). Our results
showed that 17,18-EpETE ameliorated ear swelling in all 3
experimental settings (Fig 1, C). Inflammation was ameliorated
evenwhen 17,18-EpETEwas given only on day 5 or 6, suggesting
that 17,18-EpETE suppresses inflammation in the setting of
contact hypersensitivity by targeting the elicitation phase
(Fig 1, C).
Furthermore, we confirmed that treatment with 17,18-EpETE
was effective when it was administered orally or topically to
mice (see Fig E3 in this article’s Online Repository at
www.jacionline.org). Indeed, pharmacokinetic analysis of
17,18-EpETE indicated that a single oral dose of
17,18-EpETE was absorbed into the plasma by 1 to 2 hours after
administration (see Fig E4 in this article’s Online Repository at
www.jacionline.org). Collectively, these findings demonstrate
that 17,18-EpETE is an effective lipid metabolite to control
contact hypersensitivity both preventively and therapeutically
through several administrative routes.
17,18-EpETE does not interfere with iSALT
formation, T-cell activation, or macrophage
phenotypes
We next examined which types of immune cells were affected
by the 17,18-EpETE treatment. A recent study has shown that
iSALT formation plays an important role in the elicitation phase
of skin inflammation by inducing the activation and proliferation
of effector or pathologic T cells.26 Flow cytometric analysis
revealed that intraperitoneal treatment with 17,18-EpETE only
minimally affected the numbers of DCs and T cells in inflamed
skin (see Figs E5 and E6, A, in this article’s Online Repository
at www.jacionline.org). Indeed, 17,18-EpETE had little effect
on the proliferation of T cells (see Fig E6, B). In contrast, topical
application of dexamethasone reduced the number of T cells in
inflamed skin (see Fig E6, A), suggesting that 17,18-EpETE and
dexamethasone exert anti-inflammatory properties through
different mechanisms.
FIG 2. 17,18-EpETE inhibits neutrophil mobility and infiltration of the skin. A-H, Mice were injected
intraperitoneally with either 17,18-EpETE or vehicle on days 0 and 5 at 30 minutes before DNFB application.
Ear samples were obtained on day 7. Fig 2, A, Cells were isolated from mouse ears and used for flow
cytometric analysis. Numbers indicate the percentage of Ly6G1CD11b1 neutrophils. Data are representative
of 3 independent experiments. Fig 2, B, Numbers of neutrophils were calculated on the basis of total cell
numbers and flow cytometric data. Data are combined from 3 independent experiments, and each point
represents data from individual mice. Center values indicatemedians. Statistical significance was evaluated
by using 1-way ANOVA: **P < .01 and ****P < .0001. N.S., Not significant. Fig 2, C, Ear samples were used
for tissue staining. Data are representative of 5 independent experiments. Dotted circles indicate the area of
neutrophil infiltration. Scale bars 5 100 mm. The number of Ly6G1 neutrophils per field (magnification
3200) was counted. Data are expressed as means 6 SDs (n 5 4-12). Statistical significance was evaluated
by using 1-way ANOVA: ***P < .001 and ****P < .0001. N.S., Not significant. Fig 2, D and E, Expression of
Ki67 and Annexin V in Ly6G1CD11b1 neutrophils was examined by using flow cytometry to assess neutro-
phil proliferation (Fig 2, D) and survival (Fig 2, E), respectively. Center values indicate medians. Statistical
significance was evaluated by using the Mann–Whitney test. N.S., Not significant. Fig 2, F, For in vivo label-
ing of neutrophils, FITC–anti-Ly6G mAb was injected intravenously on day 7 in the contact hypersensitivity
model; 30 minutes after injection, cells were isolated from the ears and examined by using flow cytometry.
Numbers of FITC1 neutrophils were calculated by using total cell numbers and flow cytometric data. Data
are combined from 2 independent experiments (n 5 6 to 12). Center values indicate medians. Statistical
significance was evaluated by using 1-way ANOVA: *P < .05. N.S., Not significant. Fig 2, G, Ear tissues
were homogenized for isolation of mRNA, and quantitative RT-PCR analysis was performed to measure
Cxcl1, Cxcl2, and G-CSF expression, which was normalized to that of Actb. Data are expressed as
means 6 SDs (3 replicate measurements) and representative of 2 independent experiments. Statistical
significance was evaluated by using 1-way ANOVA. N.S., Not significant. Fig 2, H, Evans blue solution
was injected intravenously at 1 hour before analysis on day 7. The amount of Evans blue dye extracted
was measured at OD620. Center values indicate medians. Statistical significance was evaluated by using
1-way ANOVA. N.S., Not significant. I, Intravital 2-photon imaging of DNFB-induced inflamed skin.
Neutrophils and microvasculature were visualized by means of intravenous injection of FITC–anti-Ly6G
mAb (green) and Qtracker 655 (far-red), respectively. The blue color indicates collagen fibers. Scale
bar 5 100 mm. J, Imaging analysis of neutrophil mobility in the skin before and after intravenous injection
of 17,18-EpETE. Colored lines show associated trajectories of the cells. K, Summary of mean tracking
velocities of neutrophils before and after treatment ofmice with 17,18-EpETE. Data points (before treatment,
n 5 135; after treatment, n 5 136) represent values for individual cells compiled from 3 independent
experiments. Center values indicate medians. Statistical significance was evaluated by using the
Mann–Whitney test: ****P < .0001.
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We next examined T-cell cytokine production over time, and
found that large numbers of IFN-g–producing T cells were
present on day 6, 1 day after elicitation of hypersensitivity (see
Fig E6), and further that 17,18-EpETE did not inhibit cytokine
production (eg, IFN-g and IL-17A; see Fig E6, C-E) in inflamed
skin. Consistent with those findings, histologic analysis showed
that 17,18-EpETE did not inhibit formation of the DC- and
T cell–containing iSALT (see Fig E6, F).
In addition to T cells, macrophages play an important role in
the development of contact hypersensitivity by inducing iSALT
formation.26 In accordance with the findings described above,
intraperitoneal treatment with 17,18-EpETE did not alter the
number of skin macrophages (see Fig E6, G) or their phenotypes,
as judged by expression of Tnfa and Chi3l3 as M1 and M2
markers, respectively (see Fig E6, H). Taken together, these
results indicate that 17,18-EpETE has minimal effects on the
function of macrophages, DCs, and T cells in the skin.
17,18-EpETE decreases the number of neutrophils
by impairing their mobility
Given that depletion of neutrophils prevents development of
inflammation,20,22,23 neutrophils play a crucial role in induction
of contact hypersensitivity. Neutrophils express FasL and
perforin, which play important roles in the development of
contact hypersensitivity40; however, intraperitoneal treatment
with 17,18-EpETE did not alter expression levels of these factors
(see Fig E7 in this article’s Online Repository at www.jacionline.
org). In contrast, compared with untreated mice with contact
hypersensitivity, those given intraperitoneal treatment with
17,18-EpETE had fewer neutrophils in the skin (Fig 2, A and
B). Consistent with our findings regarding ear swelling in mice
(Fig 1), 17,18-diHETE did not influence skin neutrophil numbers
(Fig 2, A andB). Indeed, histologic analysis showed a reduction in
numbers of Ly6G1 neutrophils in the skin of 17,18-EpETE– but
not 17,18-diHETE–treated mice (Fig 2, C).
We then hypothesized that 17,18-EpETE might reduce neutro-
phil numbers in the skin by modulating either (1) neutrophil
proliferation, (2) neutrophil survival, or (3) infiltration of
neutrophils into the skin. To test the effect of 17,18-EpETE on
the proliferation and survival of neutrophils, we stained
neutrophils with Ki67 and Annexin V, respectively. Flow
cytometric analysis revealed that 17,18-EpETE did not alter
neutrophil proliferation (Fig 2, D) or the percentage of Annexin
V1 apoptotic neutrophils (Fig 2, E) in the skin. These findings
exclude 2 possibilities regarding the effect of 17,18-EpETE on
the proliferation and survival of neutrophils in the skin.
To address the possibility that 17,18-EpETE affects neutrophil
infiltration into the skin, we used an in vivo labeling system based
on FITC-conjugated anti-Ly6G mAb.32,33 Infiltration of
FITC-labeled neutrophils was detected in the skin of
mock-treated mice after induction of contact hypersensitivity,
but their numbers were significantly decreased in the skin of
17,18-EpETE–treated mice (Fig 2, F). This finding showed that
17,18-EpETE treatment inhibited infiltration of neutrophils
from the blood circulation into the skin of mice with contact
hypersensitivity. Although CXCL1, CXCL2, and G-CSF are
known to be neutrophil-recruiting chemokines and cytokines,19,20
intraperitoneal injection of 17,18-EpETE did not affect their gene
expression in inflamed skin (Fig 2, G). In addition, the amount of
G-CSF protein in serum was unchanged by intraperitoneal
injection of 17,18-EpETE (see Fig E8 in this article’s Online
Repository at www.jacionline.org). Furthermore, intraperitoneal
injection of 17,18-EpETE had no effect on vascular permeability
(Fig 2, H).
We then used intravital 2-photon microscopy to examine
in vivo neutrophil mobility in the skin of mice with contact
hypersensitivity (Fig 2, I). This analysis revealed that neutrophil
mobility in the skin was impaired after intravenous treatment
with 17,18-EpETE (Fig 2, J and K, and see Videos E1 and E2
in this article’s Online Repository at www.jacionline.org). These
findings together suggest that 17,18-EpETE directly regulates
neutrophil mobility without affecting chemokine expression or
vascular permeability.
17,18-EpETE acts through GPR40 to control
neutrophil-mediated contact hypersensitivity
We next aimed to elucidate the molecular mechanism
underlying the anti-inflammatory properties of 17,18-EpETE.
The anti-inflammatory effect of 17,18-EpETE reportedly is
mediated by PPARg,10 but unlike rosiglitazone, a PPARg agonist,
17,18-EpETE only weakly activated PPARg (unpublished data).
Therefore we conducted TGF-a shedding assays to identify the
GPR for 17,18-EpETE.36 Among several types of GPRs,
17,18-EpETE strongly activated GPR40, weakly activated
GPR120, and did not activate GPR41, GPR43, or GPR84
(Fig 3). Although EPA is recognized by GPR40,15 its activation
activity was much weaker than that of 17,18-EpETE (Fig 4, A).
In addition, 17,18-diHETE did not activate GPR40 (Fig 4, A),
which is consistent with its lack of anti-inflammatory activity
(Fig 1, A and B). Therefore 17,18-EpETE is a unique lipid
metabolite in that it is a strong agonist of GPR40.
These findings led us to examine whether the anti-
inflammatory effects of 17,18-EpETE depend on GPR40. To
address this issue, we treated mice intraperitoneally
with GW1100, a GPR40 antagonist, at 30 minutes before
intraperitoneal administration of 17,18-EpETE in the DNFB-
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FIG 3. 17,18-EpETE preferentially activates GPR40, weakly activates
GPR120, but does not activate GPR41, GPR43, or GPR84. HEK293 cells
were transfected with the indicated receptors, and TGF-a shedding assays
were performed by using various concentrations of 17,18-EpETE.
Data are expressed as means 6 SDs (3-6 replicate measurements) and
representative of 2 independent experiments.
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FIG 4. 17,18-EpETE acts through GPR40 to control neutrophil-mediated contact hypersensitivity. A, The
TGF-a shedding assay was performed to examine the reactivity of GPR40-expressing cells to various con-
centrations of 17,18-EpETE, 17,18-diHETE, and EPA. Data are expressed as means6 SDs (3-6 replicate mea-
surements) and representative of 2 independent experiments. B, At both the sensitization and elicitation
phases, mice were injected intraperitoneally with either GW1100 or vehicle 30 minutes before intraperito-
neal 17,18-EpETE injection; mice were then stimulated with DNFB at 30 minutes after intraperitoneal
17,18-EpETE injection. Ear swelling (left) and numbers of Ly6G1CD11b1 neutrophils (right) were evaluated
on day 7. Data are combined from 3 independent experiments, and each point represents data from an in-
dividual mouse. Center values indicate medians. Statistical significance was evaluated by using 1-way AN-
OVA: **P < .01 and ****P < .0001. N.S., Not significant. C, Ffar11/1 mice and Ffar12/2 mice were injected
intraperitoneally with either 17,18-EpETE or vehicle at 30 minutes before DNFB treatment at both the sensi-
tization and elicitation phases. Ear swelling (left) and numbers of Ly6G1CD11b1 neutrophils (right) were
evaluated on day 7. Data are combined from 3 independent experiments, and each point represents data
from an individual mouse. Center values indicate medians. Statistical significance was evaluated by using
1-way ANOVA: *P < .05, ***P < .001, and ****P < .0001. N.S., Not significant.
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with GW1100 abolished the inhibitory effect of 17,18-EpETE.
Indeed, mice that received both 17,18-EpETE and GW1100 had
inflammatory symptoms (ie, ear swelling and neutrophil infiltra-
tion; Fig 4, B). To further confirm the involvement of GPR40 in
the 17,18-EpETE–mediated inhibitory activity, we used mice
lacking GPR40 (Ffar12/2 mice).16 As expected, 17,18-EpETE
had little effect on ear swelling and neutrophil numbers in the
skin of Ffar12/2 mice (Fig 4, C). Given that GPR40 expression
exerts anti-inflammatory effects, we expected that fasiglifam
(TAK-875), an agonist of GPR40,41 would lead to an
anti-inflammatory response as well. However, in contrast to
17,18-EpETE, TAK-875 did not inhibit ear swelling (see Fig E9
in this article’s Online Repository at www.jacionline.org).
Pivotal roles of GPR40 in the control of neutrophil
trafficking
A previous study showed that GPR40 is expressed in the skin.42
To address whether hematopoietic cells, nonhematopoietic cells,
or both are required for the GPR40-mediated inhibition of
contact hypersensitivity, we used wild-type and Ffar12/2 mice
to generate bone marrow chimeras. Irradiated wild-type mice
that received Ffar12/2 bone marrow cells had contact hypersen-
sitivity even after intraperitoneal injection with 17,18-EpETE
(Fig 5, A). In contrast, irradiated Ffar12/2 mice given wild-type
bone marrow cells showed inhibition of contact hypersensitivity
after intraperitoneal injection with 17,18-EpETE (Fig 5, A).
Although GPR40 is expressed reportedly on nonhematopoietic
cells, such as keratinocytes,42 our results indicate that GPR40
expression on hematopoietic cells is required to exert the
anti-inflammatory properties of 17,18-EpETE.
We next examined which hematopoietic cells expressed
GPR40 in the inflammatory skin tissue and thus were responsible
for the specific reactivity to 17,18-EpETE. We purified several
populations of hematopoietic cells with increased numbers in
inflamed skin and found that GPR40 expression was absent or
negligible in T cells, macrophages, mast cells, and eosinophils but
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FIG 5. GPR40 expressed on neutrophils plays a pivotal role in the control of neutrophil trafficking in the
setting of contact hypersensitivity. A, Bone marrow transplantation was conducted to evaluate the require-
ment of GPR40 on hematopoietic or nonhematopoietic cells for inhibition of contact hypersensitivity by
17,18-EpETE. Contact hypersensitivity was induced by DNFB in bone marrow chimera mice, and ear swelling
was evaluated on day 7. Micewere injected intraperitoneally with either 17,18-EpETE or vehicle on days 0 and
5 at 30minutes before DNFB application. Data are combined from 3 independent experiments, and each point
represents data from an individual mouse. Center values indicate medians. Statistical significance was
evaluated by using the Mann-Whitney test: *P < .05. N.S., Not significant. B, CD451Gr1highCD11b1 neutro-
phils, CD451Gr1lowCD11b1macrophages, CD451F4/802CD11c1DCs, CD451CD3ε1 T cells, CD451c-Kit1FcεRI1
mast cells, and CD451 Siglec-F1CD11b1 eosinophils were isolated from DNFB-stimulated ears, and
quantitative RT-PCR analysis was performed to analyze gene expression of Ffar1. Data are expressed as
means 6 SEMs (3 replicate measurements) and representative of 2 independent experiments. N.D., Not
determined. C, Immunoblot analysis for GTP-bound and total Rac in bone marrow–derived neutrophils
isolated from Ffar11/1 or Ffar12/2 mice. Neutrophils were treated with either 17,18-EpETE or vehicle
in vitro 15 minutes before stimulation with fMLP. Similar results were obtained from 3 independent
experiments. D, Pseudopod formation was evaluated by staining neutrophils with phalloidin. Neutrophils
were treated with either 17,18-EpETE or vehicle in vitro 15 minutes before stimulation with fMLP. Data are
representative of 3 independent experiments. Arrows indicate pseudopod structures. Scale bars 5 5 mm.
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GPR40 (see Fig E10, A, in this article’s Online Repository at
www.jacionline.org). Despite expression of GPR40, numbers of
DCs and B cells in inflamed skin (see Figs E5 and E10, B) and
the amount of serum IgM antibody (see Fig E10, C) were
unchanged by intraperitoneal injection of 17,18-EpETE. Because
DCs regulate neutrophil migration through production of IL-10
and CXCL8,43,44 we examined the expression of these genes in
inflamed ear tissue. We found that 17,18-EpETE did not affect
the expression of Il10, Cxcl1, or Cxcl2 (mouse homologue of
human Cxcl8; Fig 2, G, and see Fig E11 in this article’s Online
Repository at www.jacionline.org), thus suggesting that
17,18-EpETE exerts its inhibitory effects directly on neutrophils.
We next examined the molecular mechanisms of direct effects
of 17,18-EpETE on neutrophils. Neutrophils purified from bone
marrowwere stimulated with fMLP, a bacteria-derived neutrophil
chemoattractant,45 in the absence or presence of 17,18-EpETE
in vitro. As previously reported,46 the treatment of neutrophils
with fMLP induced Rac activation, a crucial process for cell
trafficking (Fig 5, C). The fMLP-induced Rac activation was
inhibited when neutrophils isolated from wild-type, but not
Ffar12/2, mice were treated with 17,18-EpETE (Fig 5, C).
Monomeric globular actin polymerizes to form filamentous actin
(F-actin) on Rac activation at the leading edge of the cell
movement, the structure of F-actin accumulation is known as a
pseudopod.47 Indeed, 17,18-EpETE treatment blocked
fMLP-induced pseudopod formation in wild-type neutrophils
(Fig 5, D). Furthermore, we found that 17,18-EpETE had little
effect on pseudopod formation in Ffar12/2 neutrophils (Fig
5, D). In contrast, 17,18-EpETE did not affect wild-type neutro-
phils on the cell surface expression of CD18 and CXCR2, recep-
tors for adhesion molecules (eg, ICAM1) and chemokines (eg,
CXCL1 and CXCL2), both of which play important roles in
neutrophil infiltration to the skin (see Fig E12 in this article’s On-
line Repository at www.jacionline.org).48,49
These results show that 17,18-EpETE inhibits neutrophil
infiltration into the skin through activation of GPR40-mediated
signals, thereby inhibiting Rac activation and blocking
pseudopod formation in neutrophils.
17,18-EpETE ameliorates contact hypersensitivity in
cynomolgus macaques
Using the TGF-a shedding assay, we found that 17,18-EpETE
activated not onlymurine GPR40 but also the human form (Fig 3),
prompting us to examine whether the inhibitory function of
17,18-EpETE is effective in control of skin inflammation in
cynomolgus macaques. Because cynomolgus macaques are a
useful animal model for allergic diseases,50 we first confirmed
that, as in the murine model, the treatment of cynomolgus
macaques with DNFB at days 0 and 5 led to the development of
skin inflammation with eczema formation on day 7 (Fig 6, A
and B). We then topically applied 17,18-EpETE and vehicle to
separate areas of the back skin on day 7 and monitored the
progression of skin inflammation until day 10. We found that
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FIG 6. Therapeutic treatment with 17,18-EpETE ameliorates DNFB-induced contact hypersensitivity in
cynomolgusmacaques.A, Experimental protocol for induction of contact hypersensitivity by DNFB in a cyn-
omolgus macaque and its treatment with 17,18-EpETE. B, Cynomolgus macaques treated with DNFB on
days 0 and 5 had reddening and eczema of their back skin on day 7. C, Representative photographs of
the back skin obtained 3 days after the topical application of 17,18-EpETE (right side) or vehicle (left
side). D, Skin biopsy samples were embedded in paraffin blocks, and resulting sections were analyzed by
means of hematoxylin and eosin staining (top) and staining with anti-CD66abce mAb (green) and DAPI
(blue; bottom). Data are representative of 2 independent experiments (n 5 3). Asterisks denote vesicle for-
mation, and arrows indicate cell infiltration. The dotted circle delineates the area of neutrophil infiltration.
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topical application of 17,18-EpETE ameliorated skin inflamma-
tion in cynomolgus macaques. Indeed, skin reddening and
eczema were decreased in the 17,18-EpETE–treated area,
whereas these symptoms persisted in the vehicle application
area (Fig 6, C). Histologic analysis showed that topical applica-
tion of 17,18-EpETE reduced eczema-associated vesicle forma-
tion in cynomolgus macaques (Fig 6, D), and immunohistologic
analysis revealed that 17,18-EpETE application decreased the
numbers of CD66abce1 neutrophils in the skin (Fig 6, D). These
findings suggest collectively that 17,18-EpETE is an effective
compound for topical therapy of allergic skin inflammation in
cynomolgus macaques.
DISCUSSION
In this study we showed that 17,18-EpETE acts as a GPR40
ligand and achieves its antiallergic and anti-inflammatory effects
by inhibiting neutrophil mobility in both murine and cynomolgus
macaque models of contact hypersensitivity.
GPR40 was expressed in neutrophils and DCs in inflamed
skin and in splenic B cells. In contrast to its critical role
on GPR40 and thus in decreasing neutrophil mobility,
17,18-EpETE had a negligible effect on DCs and B cells.
A previous study suggested that GPR40-mediated signaling in
keratinocytes is involved in inhibition of contact hypersensi-
tivity and that topical treatment with GW9508, an agonist of
GPR40 and GPR120, inhibited the development of contact
hypersensitivity in mice by suppressing production of
CXCL10, a T-cell attractant.42 However, our bone marrow
chimera analysis showed that GPR40 expression on
hematopoietic cells rather than nonhematopoietic cells played
an important role in the control of contact hypersensitivity by
17,18-EpETE. Furthermore, we found that TAK-875, a
GPR40 agonist, was ineffective in the treatment of contact
hypersensitivity. Given that GPR40-mediated signaling
pathways, such as Gaq and Gas, are dependent on ligand
types51 and that Ga-mediated signaling pathways differ in
distinct cell subsets,52 we suppose that 17,18-EpETE targets
specific GPR40-mediated signaling to impair neutrophil
mobility without affecting the functions of DCs, B cells, and
keratinocytes.
Of note, ear swelling was decreased in Ffar12/2 mice in
comparison with Ffar11/1 mice in the setting of DNFB-
induced contact hypersensitivity, suggesting that GPR40
positively regulates the development of inflammation. However,
ear swelling was unchanged in mice treated with GW1100, a
GPR40 antagonist. In addition, neutrophil functions, such as
Rac activation and pseudopod formation, were induced normally
by fMLP in Ffar12/2 mice. Therefore our findings show that the
17,18-EpETE–mediated impairment of neutrophil mobility is
dependent on the GPR40 receptor. Although adhesion molecules
(ICAM1-CD18), chemokines (CXCL1/CXCL2-CXCR2), and a
cytokine (G-CSF) are known targets for the control of neutrophil
infiltration into the skin and the development of contact
hypersensitivity,20,48,49 their expression remained unchanged
after treatment with 17,18-EpETE. In contrast, 17,18-EpETE
prevented Rac activation through GPR40-mediated signaling in
neutrophils. Rac belongs to the Rho GTPase family, and its
conversion from its GDP form to the GTP form plays a crucial
role in cell migration because it enables Rac to interact with
scaffold protein, lamellipodin, and consequently inducing actin
filament extension.53
GPR40-mediated signals potentially could be modulated by
either Gai, Gas, or Gaq
42,51; Gai and Gas inhibit and promote
cytosolic cyclic AMP accumulation, respectively, whereas
Gaq increases the cytosolic Ca
21 level. Therefore in
17,18-EpETE–treated neutrophils GPR40-mediated signals
likely modulate the activities of protein kinases A and C, which
are regulated by cytosolic cyclic AMP and Ca21 levels,
respectively. In addition, P-Rex1 functions as a major guanine-
nucleotide-exchange factor for Rac in fMLP stimulation, and
the activity of P-Rex1 is known to be inhibited by protein kinase
A or enhanced by protein kinase C.54
It is noteworthy that GPR40-mediated signaling pathways
are dependent on ligand types. Indeed, ALA and DHA induce
only Gaq-mediated signals through GPR40, whereas the
synthetic GPR40 agonist AM-1638 and AM-5262 induce
both Gaq- and Gas-mediated signals.
51 In addition, Gaq plus
Gas dual agonists appeared to induce incretin secretion more
efficiently than did a Gaq single-targeting agonist.
51 It remains
to be investigated which Ga protein(s) are stimulated by
17,18-EpETE, but our current findings imply that the
17,18-EpETE–GPR40 axis is likely to signal through
Gas-mediated pathways, which lead to activation of protein
kinase A and consequent inhibition of the guanine-
nucleotide-exchange factor for Rac activity of P-Rex1.
We found that 17,18-EpETE ameliorated contact hypersensi-
tivity not only preventively but also therapeutically. After their
infiltration into an inflammatory site, neutrophils produce chem-
ical mediators, such as myeloperoxidase and CXCL10.55,56
Reportedly, Rac activation is required for neutrophil degranula-
tion,57 suggesting that 17,18-EpETE might prevent neutrophil
degranulation and cell mobility. Furthermore, expression of
FasL and perforin by neutrophils is required for the development
of contact hypersensitivity.40 Therefore, in addition to inhibiting
neutrophil trafficking into the skin, therapeutic treatment of
17,18-EpETE can exert antiallergy and anti-inflammatory proper-
ties by inhibiting the degranulation of neutrophils (eg, by
affecting perforin and myeloperoxidases) or their expression of
cytotoxic molecules (eg, FasL and perforin). However, our anal-
ysis indicated that 17,18-EpETE treatment had no effect on
expression of FasL and perforin in neutrophils, suggesting that
the control of neutrophil infiltration is the primary biological
target of 17,18-EpETE.
Our current study shows that a strong GPR40 ligand ability and
the antiallergic and anti-inflammatory properties of 17,18-EpETE
require its epoxy structure. Indeed, 17,18-diHETE exerts neither
GPR40 signals nor antiallergic inflammatory properties.
Conversion from 17,18-EpETE into 17,18-diHETE is mediated
by soluble epoxide hydrolase; reportedly, inhibition of epoxide
hydrolase ameliorates inflammatory responses, such as
hypertension, diabetes, and pain pathways, thus providing organ
protection in models of cardiac, renal, and brain injury.58 In
addition, conversion of EPA into 17,18-EpETE is another key
step for its antiallergy and anti-inflammatory effects.
17,18-EpETE is converted from EPA by CYP. It is known that
CYPs has polymorphisms.59 In addition, among the CYP subfam-
ily, CYP1A, CYP2C, and CYP2J can synthesize 17,18-EpETE
from EPA.60-62 Therefore the generation and conversion of
17,18-EpETE appear to be critical determinants in the control
of allergic and inflammatory diseases.
17,18-EpETE ameliorated contact hypersensitivity in mice and
cynomolgus macaques by inhibiting neutrophil mobility.
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Neutrophils are known to play key roles in other forms of
dermatitis, such as atopic dermatitis and psoriasis,63,64 impli-
cating the effectiveness of 17,18-EpETE to control of various
kinds of dermatitis. In addition, our previous work showed that
17,18-EpETE inhibited the development of type I allergic re-
sponses by suppressing mast cell degranulation.9 Because mast
cells do not express GPR40, another cell population was likely
responsible for the antiallergic properties of 17,18-EpETE in
the intestine. Regarding this issue, GPR40-mediated signaling
is reported to enhance the intestinal epithelial barrier.65 Because
intestinal allergy is associated with a ‘‘leaky gut,’’66 it is plausible
that 17,18-EpETE treatment inhibits mast cell degranulation by
decreasing allergen entry into the body. These findings suggest
collectively that 17,18-EpETE is a prospective compound for
the prevention and treatment of various types of allergy and
inflammation in several tissues.
A compound’s route of administration is an important factor in
its clinical utility. In this sense 17,18-EpETE is clinically
attractive because it is effective not only through systemic
injection but also through oral and topical application. Therefore
17,18-EpETE might act on circulating neutrophils, as well as
those in skin lesions, after delivery to the tissue from the
bloodstream.
We also found that the anti-inflammatory activity of dexa-
methasone was stronger than that of 17,18-EpETE, presumably
because of dexamethasone’s additional effect on T cells.
Because a reduction in T-cell numbers can increase the risk of
infectious diseases, we might reserve the use of steroids for
cases of severe inflammation and then, once the severity has
decreased, change to 17,18-EpETE, which had few effects on T-
cell function.
In addition, we recently reported that the EPA-derived v3 lipid
mediator resolvin E1 inhibited DC trafficking in the setting of
contact hypersensitivity.28 Indeed, resolvin E1 inhibited both the
sensitization and elicitation phases, including iSALT formation
and subsequent DC-induced inflammatory cytokine production
(eg, IFN-g) from T cells. The different effects of resolvin E1
and 17,18-EpETE probably reflect the different receptors tar-
geted. Resolvin E1 is a partial agonist of BLT167 and inhibited
the development of contact hypersensitivity through attenuation
of leukotriene B4–BLT1 signaling in DCs.
28 In contrast, 17,18-
EpETE activated GPR40-mediated signals in neutrophils to
inhibit their mobility. Our preliminary experiments indicated
that a mixture of 17,18-EpETE and resolvin E1 decreased the
numbers of DCs and IFN-g–producing T cells, as well as neutro-
phil counts, in inflamed skin (unpublished data). Thus 17,18-
EpETE and resolvin E1 can exert synergic anti-inflammatory ef-
fects on skin inflammation.
Therefore EPA-derived v3 lipid mediators (ie, 17,18-EpETE
and resolvin E1) exert their antiallergy and anti-inflammatory
properties in the setting of contact hypersensitivity by targeting
different immune cell populations (eg, neutrophils and DCs) that
express different receptors (eg, GPR40 and BLT1), thus providing
a new therapeutic strategy through combined use of both lipid
mediators.
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Key messages
d Contact hypersensitivity is ameliorated by 17,18-EpETE,
a lipid metabolite of EPA.
d 17,18-EpETE activates GPR40 on neutrophils and in-
hibits their infiltration to the site of inflammation.
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FIG E1. Chronologic analysis of ear swelling in DNFB-induced contact hypersensitivity in mice. A, Experi-
mental protocol for induction of contact hypersensitivity by DNFB and treatment with 17,18-EpETE. At
both the sensitization and elicitation phases, mice were injected intraperitoneally with either 17,18-EpETE
or vehicle at 30 minutes before application of DNFB. Ear thickness was evaluated by using a micrometer.
Ear swelling was calculated as follows: (Ear thickness [in micrometers] after DNFB application)2 (Ear thick-
ness [in micrometers] before DNFB application) 5 Dmicrometers. B, Ear swelling was analyzed at the indi-
cated time points. Data are expressed as means 6 SEMs (n 5 4 to 24).
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FIG E2. 17,18-EpETE does not affect gene expression of various antimicrobial peptides. Ear tissues were
obtained on day 7 and homogenized for isolation of mRNA, and quantitative RT-PCR analysis was
performed to measure cathelicidin, defensin-b1, and defensin-b2 expression, which was normalized to that
of Actb. Data are expressed as means 6 SDs (3 replicate measurements) and representative of 2 indepen-
dent experiments. Statistical significance was evaluated by using ordinary 1-way ANOVA. N.S., Not
significant.
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FIG E3. 17,18-EpETE is effective not only through the intraperitoneal route
but also through the oral and topical routes. At both the sensitization and
elicitation phases, mice were treated with 17,18-EpETE (dose per time
point: 100 ng administered intraperitoneally [ip] or 1 mg administered orally
[po] or topically [skin]) through the indicated route at 30 minutes before
DNFB application. Ear swelling was evaluated on day 7. Data are combined
from 3 independent experiments, and each point represents data from an
individual mouse. Center values indicate medians. Statistical significance
was evaluated by using 1-way ANOVA: **P < .01 and ****P < .0001.
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FIG E4. Pharmacokinetic analysis of 17,18-EpETE. Plasma samples were
collected at indicated time points after oral administration of 17,18-EpETE.
The amount of 17,18-EpETE was quantified by using liquid chromatog-
raphy–tandem mass spectrometry. Data are expressed as means 6 SDs
(n 5 3).
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FIG E5. Numbers of DCs in inflamed skin are unchanged by 17,18-EpETE. Mice were injected intraperito-
neally with either 17,18-EpETE or vehicle on days 0 and 5 at 30 minutes before DNFB application. Ear
samples were obtained on day 7. Numbers of DCs were calculated by using total cell numbers and flow
cytometric data of indicated DC populations. Data are representative of 2 independent experiments, and
each point represents data from an individual mouse. Center values indicate medians. Statistical signifi-
cance was evaluated by using 1-way ANOVA. N.S., Not significant.
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FIG E6. iSALT formation and T-cell activation are not disrupted by 17,18-EpETE. A,Mice were treated topi-
cally with either 17,18-EpETE, dexamethasone, or vehicle on days 0 and 5 at 30 minutes before DNFB appli-
cation. Ear samples were obtained on day 7. Numbers of CD451CD3ε1 live T cells were calculated by using
total cell numbers and flow cytometric data. Data are representative of 2 independent experiments, and
each point represents data from an individual mouse. Center values indicate medians. Statistical signifi-
cance was evaluated by using 1-way ANOVA: *P < .05. N.S., Not significant. B, Mice were injected
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FIG E7. 17,18-EpETE does not affect expression of FasL and perforin in neutrophils. Mice were injected
intraperitoneally with either 17,18-EpETE or vehicle on days 0 and 5 at 30 minutes before DNFB application.
Ly6G1CD11b1 neutrophils harvested from the skin on day 6 were examined by using flow cytometry to
determine the expression of FasL and perforin. Similar results were obtained in 2 independent experiments.
intraperitoneally with either 17,18-EpETE or vehicle on days 0 and 5 at 30 minutes before DNFB application.
Ear samples were obtained on day 7. The percentage of Ki671 cells in the CD3ε1 live T-cell fraction was
shown. Data are combined from 3 independent experiments, and each point represents data from individual
mice. Center values indicate medians. Statistical significance was evaluated by using 1-way ANOVA. N.S.,
Not significant. C,Mice were injected intraperitoneally with either 17,18-EpETE or vehicle on days 0 and 5 at
30 minutes before DNFB application. Ear samples were obtained at indicated time points. Percentages of
IFN-g1 cells in the CD451 T-cell receptor (TCR) b1CD42 live T-cell fraction are shown. Data are expressed
as means 6 SEMs (n 5 4 to 11). D and E, Mice were injected intraperitoneally with either 17,18-EpETE or
vehicle on days 0 and 5 at 30 minutes before DNFB application. Ear samples were obtained and analyzed
by means of flow cytometry on day 6 for IFN-g1 cells in the CD451TCRb1CD4– live T-cell fraction (see Fig
E6, D) or on day 7 for IL-17A1 cells in the CD3ε1 live T-cell fraction (see Fig E6, E). Data are combined
from 3 independent experiments, and each point represents data from an individual mouse. Center values
indicate medians. Statistical significance was evaluated by using 1-way ANOVA. N.S., Not significant. F,
Mice were injected intraperitoneally with either 17,18-EpETE or vehicle on days 0 and 5 at 30 minutes before
DNFB application. Ear samples were obtained on day 7, and frozen sections were stained with the indicated
antibodies and reagents. Data are representative of 5 independent experiments. Scale bars5 100 mm. Num-
ber of CD451CD3ε1 T cells per field (magnification 3200) was counted, and data are expressed as
means 6 SDs (n 5 5-13). Statistical significance was evaluated by using 1-way ANOVA: *P < .05 and
**P < .01. N.S., Not significant. G, Mice were injected intraperitoneally with either 17,18-EpETE or vehicle
on days 0 and 5 at 30 minutes before DNFB application. Ear samples were obtained on day 7, and numbers
of F4/801CD11b1 macrophages in the skin were calculated by using flow cytometry. Data are combined
from 3 independent experiments, and each point represents data from an individual mouse. Center values
indicate medians. Statistical significance was evaluated by using 1-way ANOVA. N.S., Not significant. H,
Mice were injected intraperitoneally with either 17,18-EpETE or vehicle on days 0 and 5 at 30 minutes before
DNFB application. Ear samples were obtained on day 7, and F4/801CD11b1macrophages were isolated for
quantitative RT-PCR analysis of M1 and M2 marker expression, which was normalized to that of Actb. Data
are expressed as means 6 SDs (3 replicate measurements) and representative of 2 independent experi-
ments. Statistical significance was evaluated by using 1-way ANOVA. N.S., Not significant.
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FIG E8. 17,18-EpETE does not affect the amount of G-CSF in serum. Mice
were injected intraperitoneally with either 17,18-EpETE or vehicle on days
0 and 5 at 30 minutes before DNFB application. Serum samples were
obtained on day 7 and analyzed by means of ELISA for measurement of G-
CSF. Data are expressed asmeans6SDs (n5 5 to 8). Statistical significance
was evaluated by using 1-way ANOVA. N.S., Not significant.
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FIG E9. Contact hypersensitivity is ameliorated by 17,18-EpETE but not
TAK-875. Mice were injected intraperitoneally with either 17,18-EpETE or
TAK-875 on days 0 and 5 at 30 minutes before DNFB application. Ear
swelling was analyzed on day 7. Data are combined from 2 independent
experiments and expressed as means6 SDs (n5 8). Statistical significance
was evaluated by using 1-way ANOVA: **P < .01 and ****P < .0001. N.S.,
Not significant.
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FIG E10. 17,18-EpETE does not affect B-cell function. A, CD451B2201CD191 live B cells were isolated from
spleens, and RT-PCR analysis was performed to examine gene expression of the Ffar1 gene. Data are ex-
pressed asmeans6 SEMs (n5 7). B,Mice were injected intraperitoneally with either 17,18-EpETE or vehicle
on days 0 and 5 at 30 minutes before DNFB application. Ear samples were obtained on day 7. Numbers of
CD451B2201CD191 live B cells were calculated by using total cell numbers and flow cytometric data. Data
are expressed asmeans6SDs (n5 2-4). Statistical significance was evaluated by using 1-way ANOVA.N.S.,
Not significant. C,Mice were injected intraperitoneally with either 17,18-EpETE or vehicle on days 0 and 5 at
30 minutes before DNFB application. Serum samples were obtained on day 7 and analyzed by means of
ELISA for the measurement of IgM. Data are combined from 3 independent experiments and expressed
as means 6 SDs (n 5 12).
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FIG E11. 17,18-EpETE does not affect gene expression of Il10 in inflamed
skin. Mice were injected intraperitoneally with either 17,18-EpETE or
vehicle on days 0 and 5 at 30minutes before DNFB application. Ear samples
were obtained on day 7 and homogenized for isolation of mRNA, and quan-
titative RT-PCR analysis was performed to measure Il10 expression, which
was normalized to that of Actb. Data are expressed asmeans6 SDs (3 repli-
cate measurements) and representative of 2 independent experiments. Sta-
tistical significance was evaluated by using 1-way ANOVA. N.S., Not
significant.
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FIG E12. 17,18-EpETE does not affect expression of CD18 or CXCR2 on neutrophils. Ly6G1CD11b1 neutro-
phils harvested from skins and spleens were examined by using flow cytometry for expression of CD18 and
CXCR2, respectively, in the murine model of DNFB-induced contact hypersensitivity. Similar results were
obtained in 2 independent experiments.
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